Mylan Launches Advair Rival In Canada
Firm’s Wixela Inhub Version Is First Rival To GSK Brand
Executive Summary
Mylan has rolled out the first generic rival to GlaxoSmithKline’s Advair in Canada with the launch of its Wixela Inhub version.
Topics
- Subjects
- Launches
- Generic Drugs
- Regions
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB149698
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB149698
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.